AGMB Overview

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

Wall Street analysts forecast AGMB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGMB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Agomab Therapeutics NV revenue for the last quarter amounts to -11.99M USD, decreased

Agomab Therapeutics NV. EPS for the last quarter amounts to -12800000.00 USD, decreased

Agomab Therapeutics NV (AGMB) has 45 emplpoyees as of March 30 2026.

Today AGMB has the market capitalization of 528.79M USD.